NCT03482037View on ClinicalTrials.gov

Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

June 7, 2018

Primary Completion Date

March 27, 2019

Study Completion Date

March 27, 2019

Conditions
Neurogenic Detrusor Overactivity
Interventions
DRUG

Rec 0/0438 1 mg or Rec 0/0438 2 mg

Each vial content will be administered via the catheter used for the self-catheterization

DRUG

placebo

Each vial content will be administered via the catheter used for the self-catheterization

Trial Locations (9)

69495

Centre Hospitalier Lyon Sud Unité de Pharmacie Clinique Oncologique (essai clinique) Pavillon Marcel Bérard - Bât. 1G, Pierre-Bénite

75013

Department of Urology, Academic hospital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Pierre et Marie Curie Medical School, Sorbonne Universités, Paris

Unknown

Recordati Investigative Site, Prague

Recordati Investigative Site, Rouen

Recordati Investigative Site, Toulouse

Recordati Investigative Site, Piaseczno

Recordati Investigative Site, Rzeszów

Recordati Investigative Site, Warsaw

Recordati Investigative Site, Porto

All Listed Sponsors
lead

RECORDATI GROUP

INDUSTRY

NCT03482037 - Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury | Biotech Hunter | Biotech Hunter